We live in an exciting era in the field of oncology. Innovative efforts are accelerating cancer research and enabling a new generation of therapeutic and diagnostic technologies to help us improve the ...
Kidney cancer, though less common, demands specialized support, particularly as patients on second- and third-line therapies require long-term holistic care. Therapies for kidney cancer have ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A four-part CE activity was launched live-online in December ...
Hosted on MSN
Oncologist shares what most men miss about prostate cancer symptoms and how early screening can be life-saving
Prostate cancer is one of the most common cancers among men, but spotting it early can make all the difference. Dr. Ravi Chandran K, Consultant, Uro Oncology and Robotic Surgery, Apollo Hospitals, ...
Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the 2016 ...
OWINGS MILL, Md., Nov. 19, 2025 /PRNewswire/ -- Chesapeake Urology Associates (CUA) announced today that Chesapeake Oncology-Hematology Associates (COHA), the premier oncology group in Maryland ...
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results